Government slashes prices of 543 cancer drug brands from Nov 9

A question can test government price regulation mechanisms for pharmaceuticals, the National Pharmaceutical Pricing Authority's (NPHA) regulatory framework, and specific instances of drug price control in India. The date November 9 and the quantified price reduction example (Azacytin from ₹6,337 to ₹1,495.04) may be referenced in MCQs on healthcare economics or pharmaceutical policy.

No specific implementation concern is stated in the supplied report.

Price regulation of essential cancer drugs directly impacts healthcare accessibility for economically disadvantaged patients and reduces out-of-pocket expenditure burden on households. This intervention reflects government policy on making life-saving medicines affordable within India's healthcare system.

• 543 cancer drug brands had regulated price cuts effective from November 9. • Azacytin (100 mg azacitidine injection) price reduced to ₹1,495.04 from ₹6,337. • This reflects government price control authority's regulatory action on essential pharmaceuticals.